Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

Hammond, Sean, Meng, Xiaoli ORCID: 0000-0002-7774-2075, Mosedale, Merrie and Naisbitt, Dean J (2023) Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan. Toxicology Letters, 373. pp. 148-151.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1016/j.toxlet.2022.11.017

Abstract

Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients. An important clinical conundrum following the contraindication of tolvaptan is whether administration of agents of similar pharmacological action and structure will be tolerated. Herein, we addressed this question through the exposure of tolvaptan-responsive T-cell clones to similar pharmaceutical agents. Whilst lixivaptan and conivaptan did not activate tolvaptan-responsive T-cells, mozavaptan evoked proliferative responses comparable with tolvaptan itself, indicating that there may be collateral immunological intolerance to this compound as a product of sensitization to tolvaptan.

Item Type:	Article
Uncontrolled Keywords:	Tolvaptan, Mozavaptan, Drug-induced liver injury, T-lymphocytes, Human, ADPKD
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	02 Dec 2022 10:30
Last Modified:	22 Mar 2023 21:50
DOI:	10.1016/j.toxlet.2022.11.017
Open Access URL:	https://doi.org/10.1016/j.toxlet.2022.11.017
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3166485